Review



quantikine human vegf a elisa kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems quantikine human vegf a elisa kit
    Quantikine Human Vegf A Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1725 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantikine human vegf a elisa kit/product/R&D Systems
    Average 96 stars, based on 1725 article reviews
    quantikine human vegf a elisa kit - by Bioz Stars, 2026-06
    96/100 stars

    Images



    Similar Products

    97
    Bio-Techne corporation human vegf quantikine elisa kit
    Human Vegf Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf quantikine elisa kit/product/Bio-Techne corporation
    Average 97 stars, based on 1 article reviews
    human vegf quantikine elisa kit - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    96
    R&D Systems quantikine human vegf a elisa kit
    Quantikine Human Vegf A Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/quantikine human vegf a elisa kit/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    quantikine human vegf a elisa kit - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    95
    R&D Systems human vegf elisa kit
    Human Vegf Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human vegf elisa kit/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    human vegf elisa kit - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    96
    R&D Systems vegfa
    Abundance of proteins significantly associated with incomplete response to anti-VEGF therapy. A total of 10 proteins were found to be significantly regulated in substantial edema versus no edema. A, Upregulated proteins determined by mass spectrometry at time points 1 to 3 (T1-T3) <t>included</t> <t>afamin</t> (AFM), alpha-1B-glycoprotein (A1BG), and angiotensinogen (AGT). B, Downregulated proteins included cystatin-C (CST3), clusterin (CLU), apolipoprotein E (APOE), epidermal growth factor-containing fibulin-like extracellular matrix protein (EFEMP1), Ig lambda chain V-I (IGLV1), latent transforming growth factor beta-binding protein 2 (LTBP2), and reelin (RELN). C, The increased level of afamin was confirmed by ELISA. D, <t>VEGFA</t> concentration assessed by ELISA. There was no significant difference in VEGFA between the substantial edema and no edema groups. Box plots indicate median, min and max and first and third quartiles. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001. ELISA = enzyme-linked immunosorbent assay; LFQ = Label-Free Quantification.
    Vegfa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegfa/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    vegfa - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    95
    R&D Systems vegf
    Abundance of proteins significantly associated with incomplete response to anti-VEGF therapy. A total of 10 proteins were found to be significantly regulated in substantial edema versus no edema. A, Upregulated proteins determined by mass spectrometry at time points 1 to 3 (T1-T3) <t>included</t> <t>afamin</t> (AFM), alpha-1B-glycoprotein (A1BG), and angiotensinogen (AGT). B, Downregulated proteins included cystatin-C (CST3), clusterin (CLU), apolipoprotein E (APOE), epidermal growth factor-containing fibulin-like extracellular matrix protein (EFEMP1), Ig lambda chain V-I (IGLV1), latent transforming growth factor beta-binding protein 2 (LTBP2), and reelin (RELN). C, The increased level of afamin was confirmed by ELISA. D, <t>VEGFA</t> concentration assessed by ELISA. There was no significant difference in VEGFA between the substantial edema and no edema groups. Box plots indicate median, min and max and first and third quartiles. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001. ELISA = enzyme-linked immunosorbent assay; LFQ = Label-Free Quantification.
    Vegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    vegf - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    96
    R&D Systems human elisa kit
    Abundance of proteins significantly associated with incomplete response to anti-VEGF therapy. A total of 10 proteins were found to be significantly regulated in substantial edema versus no edema. A, Upregulated proteins determined by mass spectrometry at time points 1 to 3 (T1-T3) <t>included</t> <t>afamin</t> (AFM), alpha-1B-glycoprotein (A1BG), and angiotensinogen (AGT). B, Downregulated proteins included cystatin-C (CST3), clusterin (CLU), apolipoprotein E (APOE), epidermal growth factor-containing fibulin-like extracellular matrix protein (EFEMP1), Ig lambda chain V-I (IGLV1), latent transforming growth factor beta-binding protein 2 (LTBP2), and reelin (RELN). C, The increased level of afamin was confirmed by ELISA. D, <t>VEGFA</t> concentration assessed by ELISA. There was no significant difference in VEGFA between the substantial edema and no edema groups. Box plots indicate median, min and max and first and third quartiles. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001. ELISA = enzyme-linked immunosorbent assay; LFQ = Label-Free Quantification.
    Human Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human elisa kit/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    human elisa kit - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    R&D Systems human enzyme linked immunosorbent assay elisa development kit
    Time-Course Analysis of Angiogenesis Gene Regulation in PC3 Cells Upon EGF Stimulation and LA3IK Treatment. ( A ) Time-course heatmap showing upregulation of angiogenesis-related genes in PC3 cells following EGF stimulation at 0 h, 30 min, 1 h, and 6 h. ( B ) :(B) Heat-map displaying, for each gene, the log₂ fold-change induced by 6 h EGF versus 0 h (red ) and the subsequent log₂ fold-change observed when LA3IK was co-treated for 6 h versus EGF alone (blue) ( C ) Principal Component Analysis (PCA) plot showing the clustering and separation of RNA-seq samples from control (EGF 0 h), EGF-treated (6 h), and EGF + LA3IK-treated (6 h) in PC3 cells. ( D ) Combined RNA-seq and qPCR analysis showing LA3IK-mediated inhibition of ANGPTL4 expression. ( E ) Combined RNA-seq and qPCR analysis demonstrating reduced VEGFA expression upon LA3IK treatment. (E) <t>ELISA</t> quantification of secreted ANGPTL4 showing inhibition by LA3IK in EGF-treated PC3 cells. ( F ) ELISA analysis of ANGPTL4 levels showing time-dependent inhibition by LA3IK following EGF stimulation. ( G ) ELISA analysis of VEGFA levels showing time-dependent inhibition by LA3IK following EGF stimulation. For panels D and E, data were analyzed using a two-tailed Mann–Whitney test (nonparametric, unpaired). For F and G, a two-tailed unpaired Student’s t-test was used. Statistical significance is indicated as follows: ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001. All treatments used EGF at 10 ng/mL and LA3IK at 80 μM.
    Human Enzyme Linked Immunosorbent Assay Elisa Development Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human enzyme linked immunosorbent assay elisa development kit/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    human enzyme linked immunosorbent assay elisa development kit - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    Abundance of proteins significantly associated with incomplete response to anti-VEGF therapy. A total of 10 proteins were found to be significantly regulated in substantial edema versus no edema. A, Upregulated proteins determined by mass spectrometry at time points 1 to 3 (T1-T3) included afamin (AFM), alpha-1B-glycoprotein (A1BG), and angiotensinogen (AGT). B, Downregulated proteins included cystatin-C (CST3), clusterin (CLU), apolipoprotein E (APOE), epidermal growth factor-containing fibulin-like extracellular matrix protein (EFEMP1), Ig lambda chain V-I (IGLV1), latent transforming growth factor beta-binding protein 2 (LTBP2), and reelin (RELN). C, The increased level of afamin was confirmed by ELISA. D, VEGFA concentration assessed by ELISA. There was no significant difference in VEGFA between the substantial edema and no edema groups. Box plots indicate median, min and max and first and third quartiles. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001. ELISA = enzyme-linked immunosorbent assay; LFQ = Label-Free Quantification.

    Journal: Ophthalmology Science

    Article Title: Serial Aqueous Humor Proteomics in Diabetic Macular Edema

    doi: 10.1016/j.xops.2025.101056

    Figure Lengend Snippet: Abundance of proteins significantly associated with incomplete response to anti-VEGF therapy. A total of 10 proteins were found to be significantly regulated in substantial edema versus no edema. A, Upregulated proteins determined by mass spectrometry at time points 1 to 3 (T1-T3) included afamin (AFM), alpha-1B-glycoprotein (A1BG), and angiotensinogen (AGT). B, Downregulated proteins included cystatin-C (CST3), clusterin (CLU), apolipoprotein E (APOE), epidermal growth factor-containing fibulin-like extracellular matrix protein (EFEMP1), Ig lambda chain V-I (IGLV1), latent transforming growth factor beta-binding protein 2 (LTBP2), and reelin (RELN). C, The increased level of afamin was confirmed by ELISA. D, VEGFA concentration assessed by ELISA. There was no significant difference in VEGFA between the substantial edema and no edema groups. Box plots indicate median, min and max and first and third quartiles. ∗ P < 0.05; ∗∗ P < 0.01; ∗∗∗ P < 0.001. ELISA = enzyme-linked immunosorbent assay; LFQ = Label-Free Quantification.

    Article Snippet: Samples were diluted 500-fold for afamin (ELH-AFM-1, RayBiotech) and 2-fold for VEGFA (DVE00, R&D Systems).

    Techniques: Mass Spectrometry, Binding Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Quantitative Proteomics

    Time-Course Analysis of Angiogenesis Gene Regulation in PC3 Cells Upon EGF Stimulation and LA3IK Treatment. ( A ) Time-course heatmap showing upregulation of angiogenesis-related genes in PC3 cells following EGF stimulation at 0 h, 30 min, 1 h, and 6 h. ( B ) :(B) Heat-map displaying, for each gene, the log₂ fold-change induced by 6 h EGF versus 0 h (red ) and the subsequent log₂ fold-change observed when LA3IK was co-treated for 6 h versus EGF alone (blue) ( C ) Principal Component Analysis (PCA) plot showing the clustering and separation of RNA-seq samples from control (EGF 0 h), EGF-treated (6 h), and EGF + LA3IK-treated (6 h) in PC3 cells. ( D ) Combined RNA-seq and qPCR analysis showing LA3IK-mediated inhibition of ANGPTL4 expression. ( E ) Combined RNA-seq and qPCR analysis demonstrating reduced VEGFA expression upon LA3IK treatment. (E) ELISA quantification of secreted ANGPTL4 showing inhibition by LA3IK in EGF-treated PC3 cells. ( F ) ELISA analysis of ANGPTL4 levels showing time-dependent inhibition by LA3IK following EGF stimulation. ( G ) ELISA analysis of VEGFA levels showing time-dependent inhibition by LA3IK following EGF stimulation. For panels D and E, data were analyzed using a two-tailed Mann–Whitney test (nonparametric, unpaired). For F and G, a two-tailed unpaired Student’s t-test was used. Statistical significance is indicated as follows: ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001. All treatments used EGF at 10 ng/mL and LA3IK at 80 μM.

    Journal: Scientific Reports

    Article Title: An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR–ERBB2 heterodimerization

    doi: 10.1038/s41598-026-41933-1

    Figure Lengend Snippet: Time-Course Analysis of Angiogenesis Gene Regulation in PC3 Cells Upon EGF Stimulation and LA3IK Treatment. ( A ) Time-course heatmap showing upregulation of angiogenesis-related genes in PC3 cells following EGF stimulation at 0 h, 30 min, 1 h, and 6 h. ( B ) :(B) Heat-map displaying, for each gene, the log₂ fold-change induced by 6 h EGF versus 0 h (red ) and the subsequent log₂ fold-change observed when LA3IK was co-treated for 6 h versus EGF alone (blue) ( C ) Principal Component Analysis (PCA) plot showing the clustering and separation of RNA-seq samples from control (EGF 0 h), EGF-treated (6 h), and EGF + LA3IK-treated (6 h) in PC3 cells. ( D ) Combined RNA-seq and qPCR analysis showing LA3IK-mediated inhibition of ANGPTL4 expression. ( E ) Combined RNA-seq and qPCR analysis demonstrating reduced VEGFA expression upon LA3IK treatment. (E) ELISA quantification of secreted ANGPTL4 showing inhibition by LA3IK in EGF-treated PC3 cells. ( F ) ELISA analysis of ANGPTL4 levels showing time-dependent inhibition by LA3IK following EGF stimulation. ( G ) ELISA analysis of VEGFA levels showing time-dependent inhibition by LA3IK following EGF stimulation. For panels D and E, data were analyzed using a two-tailed Mann–Whitney test (nonparametric, unpaired). For F and G, a two-tailed unpaired Student’s t-test was used. Statistical significance is indicated as follows: ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001. All treatments used EGF at 10 ng/mL and LA3IK at 80 μM.

    Article Snippet: Quantification of secretory ANGPTL4 and VEGF in the culture medium was performed using a Human Enzyme-Linked Immunosorbent Assay (ELISA) development kit (DY3458 and DVE00) following the manufacturer’s instructions (R&D Systems).

    Techniques: RNA Sequencing, Control, Inhibition, Expressing, Enzyme-linked Immunosorbent Assay, Two Tailed Test, MANN-WHITNEY